Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0001577 (adnexitis)
 232 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ceftazidime (CAZ) was administered to patients with obstetrical and gynecological infectious diseases and we studied its clinical effect: CAZ was administered to 24 patients at a dose of 2--4 g per day (twice a day) by drip infusion over a period of 3--11 days (total 6--32 g). The subjects included 19 cases of intrauterine infection, 4 of adnexitis, and 1 of infection of the external genital organs. The overall clinical results were excellent in 6 cases and good in 18 cases, the efficacy rate being 100%. For bacteriological study, 26 strains were isolated from 16 patients. These included Gram-positive bacteria (10 strains), Gram-negative bacteria (6 strains) and anaerobes (10 strains). After CAZ treatment, 4 strains (S. mitis 1, E. coli 1, P. anaerobius 1, B. melaninogenicus 1) were eliminated, but as to the other 22 strains, the results were unknown, because we could not examine microbiology after administration. No clinical side effect or abnormality in laboratory findings was observed.
 ...
PMID:[Evaluation of the clinical effect of ceftazidime in the field of obstetrics and gynecology]. 637 Dec 96

Ceftazidime ( CAZ ) was evaluated for its clinical efficacy in a total of 12 cases, namely 3 cases of endometritis, 3 cases of intrapelvic infections, 4 cases of adnexitis and 2 cases of external genital infections. In all the cases, CAZ was administered by intravenous drip infusion, and the duration of the treatment ranged from 3 to 22 days. Daily dose was 2 g in 10 cases, and in the remaining 2 cases, daily doses were changed during the course of treatment in the range from 2 to 4 g. The clinical results of CAZ by disease were as follows; excellent in 1 case and good in 2 cases of endometritis, good in all the 3 cases of intrapelvic infections and the 4 cases of adnexitis, and excellent in 1 case and good in 1 case of external genital infections. The overall efficacy rate was 100%, namely, excellent in 2 cases and good in 10 cases of the total of 12 cases. Neither side effects nor abnormal laboratory findings attributable to CAZ were observed in any of the case. From these results, we may conclude that CAZ is a safe antibiotic with satisfactory clinical effects on gynecological infections.
 ...
PMID:[Clinical efficacy of ceftazidime in inflammatory diseases in the field of gynecology]. 637 90

Ceftazidime ( CAZ ) exhibited in vitro activity greater than cefoperazone, cefotiam, cefmetazole and cefazolin and almost equal to cefotaxime (CTX), ceftizoxime (CZX) and latamoxef ( LMOX ) against E. coli and K. pneumoniae isolated from obstetrical or gynecological infections excluding urinary tract infections. This drug demonstrated less activity than other 6 cephems against B. fragilis. Against anaerobic Gram-positive cocci, it showed less activity than other cephems. CAZ was administered to 11 patients with obstetrical and gynecological infections. The clinical results of this drug were as follows; excellent in each 1 case of parametritis , wound infection and BARTHOLIN's abscess, good in 7 cases including 1 of puerperal fever, 2 of intrauterine infection and 4 of adnexitis, and poor in 1 cases of adnexitis. No side effects or haematobiochemical abnormalities were observed throughout this trial.
 ...
PMID:[Ceftazidime: antibacterial activity and clinical efficacy in obstetrics and gynecology]. 637 92

Ceftazidime ( CAZ ), a new cephalosporin antibiotic, was fundamentally and clinically studied. The following results were obtained. Serum and internal genital tissue levels of CAZ were measured following intravenous drip infusion of 1 g for 30 minutes. Serum levels of more than 10 micrograms/ml and tissue levels of more than about 7 micrograms/ml were maintained after 2 hours to 2 hours and 30 minutes, respectively. Favourable transfer of CAZ into the pelvic dead space exudate was observed. The exudate level attained its peak of 31.54 micrograms/ml on average at 2 hours and was 16.8 micrograms/ml on average even at 8 hours after intravenous drip infusion. A total of 6 cases comprising 1 of adnexitis, 2 of pyometra, 1 of endometritis and 2 of parametritis was treated with CAZ at a dose of 0.5 approximately 2.0 g twice daily by intravenous injection or intravenous drip infusion. The clinical response was excellent in 1 case, good in 4 cases and poor in 1 case. Abnormal laboratory findings and side effects due to the drug were not noted.
 ...
PMID:[Fundamental and clinical studies of ceftazidime in the field of obstetrics and gynecology]. 637 96

Ceftazidime ( CAZ ) was studied for the transfer into intrapelvic tissues and for the clinical efficacy in the treatment of 20 cases of obstetrical and gynecological infections. Transfer into the tissues--Following intravenous 1 hour-drip infusion of 1 g, favourable transfer of CAZ into intrapelvic tissues was observed. The peak drug level of 50 approximately 66 micrograms/g was obtained at 5 approximately 36 minutes after completion of the administration. Clinical evaluation-- CAZ was administered at a daily dose of 2 approximately 4 g in 1 approximately 4 divided doses by intravenous drip infusion for 90 minutes. The subjects were patients with the following infections; pyometra (1), puerperal endometritis (3), parametritis (5), pelvioperitonitis (3), purulent lymphocytes (2), retroperitoneal abscess (1) and acute adnexitis (5). Clinical efficacy was; excellent in 15 cases, good in 3 cases and poor in 2 cases, with the overall efficacy rate of 90.0%. No notable side effects or abnormal laboratory findings were observed except for eruption in 1 case.
 ...
PMID:[Fundamental and clinical studies on ceftazidime in the field of obstetrics and gynecology]. 637 99